Icotrokinra, an oral IL-23 receptor antagonist, has been shown to effectively block IL-23-mediated STAT3 phosphorylation and IFN-γ production in NK cells, showing significant anti-inflammatory effects. This drug mainly acts on the IL-23 receptor in the process of pathogenic T cell activation in plaque psoriasis, so it has potential application value in the research fields of psoriasis, psoriatic arthritis and inflammatory bowel disease.